Who makes Brand name travoprost?

Brand name travoprost is developed by Université de Sherbrooke.

What development phase is Brand name travoprost in?

Brand name travoprost is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Brand name travoprost

Université de Sherbrooke · FDA-approved active Small molecule Quality 2/100

Travoprost, marketed by Université de Sherbrooke, is an established drug in the glaucoma treatment market. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-2028, which could significantly impact revenue.

At a glance

Generic name	Brand name travoprost
Also known as	Travatan Z
Sponsor	Université de Sherbrooke
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Brand name travoprost CI brief — competitive landscape report
Brand name travoprost updates RSS · CI watch RSS
Université de Sherbrooke portfolio CI